1. Home
  2. |Professionals
  3. |Eline D'Joos

Eline D'Joos

Associate | She/Her/Hers
Associate | She/Her/Hers
ZWRqb29zQGNyb3dlbGwuY29t
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Eline D’Joos is a life sciences associate in Crowell & Moring’s Brussels office. Her practice focuses on regulatory issues and commercial transactions in the life science sector, as well as interplays with general intellectual property and data protection questions. 

Eline has advised multinational companies and start-ups as well as research institutes in the pharmaceutical, biotech, and medical devices sectors on a variety of complex matters, including clinical trials, product approvals, regulatory incentives, market access, biosimilars, orphan drugs, pediatrics, and Belgian supplementary protection certificates. Digital transformation in the health sector is also one of Eline’s main focus areas.

Eline also has experience in drafting and negotiating high value IP licenses, R&D collaborations, and commercial agreements. In addition, she has assisted with mergers and acquisitions of life sciences companies as well as patent infringement proceedings and preliminary injunctions.

Career & Education

    • Catholic University of Leuven, Bachelor of law, magna cum laude (best bachelor student award), 2017
    • Catholic University of Leuven, Research master of law, magna cum laude, 2019
    • Catholic University of Leuven, Master of education, cum laude, 2020
    • Catholic University of Leuven, Bachelor of law, magna cum laude (best bachelor student award), 2017
    • Catholic University of Leuven, Research master of law, magna cum laude, 2019
    • Catholic University of Leuven, Master of education, cum laude, 2020

    • Belgium
    • Belgium

    • Dutch
    • English
    • French
    • Dutch
    • English
    • French

Eline's Insights

Client Alert | 5 min read | 03.22.26

EU Pharma Package: Regulatory Data Protection Compromise Proposal

In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions....

View All Insights

Insights

Client Alert | 5 min read | 03.22.26

EU Pharma Package: Regulatory Data Protection Compromise Proposal

Client Alert | 2 min read | 03.12.26

The EU Pharma Package: Formal Adoption in Sight

Publication | 02.03.26

Drowning in EU regulations? Five tips for surviving the deluge of new rules

Client Alert | 13 min read | 12.22.25

European Commission Proposes Biotech Act to Boost Health Biotechnology in the EU

View All Insights

Practices

Industries

Eline's Insights

Client Alert | 5 min read | 03.22.26

EU Pharma Package: Regulatory Data Protection Compromise Proposal

In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions....

View All Insights